Kazia Regains Nasdaq Compliance Following $50 Million Institutional Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Source: PRnewswire
- Compliance Restoration: On December 18, 2025, Kazia received confirmation from Nasdaq that it has regained compliance with the $2.5 million minimum stockholders' equity requirement, leading to the cancellation of a previously scheduled hearing and allowing its American Depositary Shares to continue trading on The Nasdaq Capital Market.
- Financing Strength: The company recently completed a $50 million private placement of equity securities, led by healthcare-focused institutional investors, which significantly bolstered its balance sheet and stockholders' equity position.
- Strategic Focus: Kazia's CEO stated that with compliance restored, the company is well-positioned to advance its clinical programs, particularly the development of paxalisib for brain cancer and advanced breast cancer, thereby enhancing long-term shareholder value.
- Increased Market Flexibility: The restoration of compliance provides greater clarity for investors and enhances the company's capital markets flexibility, aiding its ongoing efforts to advance its clinical-stage oncology pipeline.
Analyst Views on KZIA
Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.930
Low
18.00
Averages
19.00
High
20.00
Current: 7.930
Low
18.00
Averages
19.00
High
20.00
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
